PL2891651T3 - Sól aminy i jej kryształy - Google Patents

Sól aminy i jej kryształy

Info

Publication number
PL2891651T3
PL2891651T3 PL13832178T PL13832178T PL2891651T3 PL 2891651 T3 PL2891651 T3 PL 2891651T3 PL 13832178 T PL13832178 T PL 13832178T PL 13832178 T PL13832178 T PL 13832178T PL 2891651 T3 PL2891651 T3 PL 2891651T3
Authority
PL
Poland
Prior art keywords
crystals
amine salt
amine
salt
Prior art date
Application number
PL13832178T
Other languages
English (en)
Inventor
Kousuke Tani
Akihiro Kinoshita
Keisuke Hanada
Yoshiyuki Aratani
Takahiro Nekado
Atsushi Shimabukuro
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Publication of PL2891651T3 publication Critical patent/PL2891651T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL13832178T 2012-08-31 2013-08-30 Sól aminy i jej kryształy PL2891651T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012191080 2012-08-31
EP13832178.1A EP2891651B1 (en) 2012-08-31 2013-08-30 Amine salt and crystals thereof

Publications (1)

Publication Number Publication Date
PL2891651T3 true PL2891651T3 (pl) 2017-08-31

Family

ID=50183705

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13832178T PL2891651T3 (pl) 2012-08-31 2013-08-30 Sól aminy i jej kryształy

Country Status (24)

Country Link
US (1) US9643940B2 (pl)
EP (1) EP2891651B1 (pl)
JP (1) JP6131956B2 (pl)
KR (1) KR102119619B1 (pl)
CN (1) CN104603117B (pl)
AU (1) AU2013309872B2 (pl)
BR (1) BR112015004459B1 (pl)
CA (1) CA2882732C (pl)
DK (1) DK2891651T3 (pl)
ES (1) ES2623788T3 (pl)
HK (1) HK1210168A1 (pl)
HU (1) HUE032816T2 (pl)
IL (1) IL237432B (pl)
MX (1) MX344385B (pl)
MY (1) MY177737A (pl)
NZ (1) NZ705340A (pl)
PH (1) PH12015500389A1 (pl)
PL (1) PL2891651T3 (pl)
PT (1) PT2891651T (pl)
RU (1) RU2658823C2 (pl)
SG (1) SG11201501451SA (pl)
TW (1) TWI597274B (pl)
WO (1) WO2014034902A1 (pl)
ZA (1) ZA201501374B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022001388A (es) * 2019-08-04 2022-03-25 Yeda Res & Dev Proceso para la preparacion de fluensulfona.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (pl) 1970-06-10 1975-02-04
JPS5231404B1 (pl) 1971-04-28 1977-08-15
FR2204408A1 (en) * 1972-10-27 1974-05-24 Wirth Pierre Phenylbutazone salts - sol in water and well tolerated
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
JPS60197667A (ja) 1984-03-19 1985-10-07 Ono Pharmaceut Co Ltd 6―ケト―プロスタグランジン類似化合物及びその製造方法
PT1008588E (pt) 1997-02-10 2003-09-30 Ono Pharmaceutical Co Derivados da 11,15-o-diaklquil-prostaglandina e processo de producao dos mesmos e farmaco que os contem como ingrediente activo
JPH11130678A (ja) 1997-08-27 1999-05-18 Kaken Pharmaceut Co Ltd 神経圧迫による神経障害改善剤
US7608637B2 (en) 2001-07-23 2009-10-27 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient
RU2306309C2 (ru) 2002-03-05 2007-09-20 Оно Фармасьютикал Ко., Лтд. Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
US7551916B2 (en) 2002-07-11 2009-06-23 Nokia Corporation Method and device for automatically changing a digital content on a mobile device according to sensor data
JP4582456B2 (ja) 2003-01-21 2010-11-17 小野薬品工業株式会社 8−アザプロスタグランジン誘導体およびその医薬用途
JPWO2004089411A1 (ja) 2003-04-03 2006-07-06 小野薬品工業株式会社 脊柱管狭窄症治療剤
WO2005053707A1 (ja) 2003-12-05 2005-06-16 Ono Pharmaceutical Co., Ltd. 馬尾神経組織血流増加剤
JPWO2005061492A1 (ja) 2003-12-22 2007-07-12 小野薬品工業株式会社 含窒素複素環化合物およびそれらを有効成分とする薬剤
JP4888775B2 (ja) * 2004-08-10 2012-02-29 小野薬品工業株式会社 Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
EP2308510B1 (en) * 2005-06-03 2016-03-16 Ono Pharmaceutical Co., Ltd. Agent for regeneration and/or protection of nerves
JP5630264B2 (ja) * 2008-06-06 2014-11-26 小野薬品工業株式会社 膀胱排尿筋収縮および尿道括約筋弛緩剤
CN102803239B (zh) 2009-06-10 2015-04-15 小野药品工业株式会社 具有膀胱排尿肌收缩活性和尿道括约肌舒张活性的化合物

Also Published As

Publication number Publication date
EP2891651B1 (en) 2017-03-08
ES2623788T3 (es) 2017-07-12
CN104603117B (zh) 2018-03-23
NZ705340A (en) 2018-06-29
US9643940B2 (en) 2017-05-09
TWI597274B (zh) 2017-09-01
CN104603117A (zh) 2015-05-06
SG11201501451SA (en) 2015-04-29
PH12015500389B1 (en) 2015-04-27
KR20150047500A (ko) 2015-05-04
CA2882732C (en) 2021-03-30
JP6131956B2 (ja) 2017-05-24
PT2891651T (pt) 2017-05-08
KR102119619B1 (ko) 2020-06-05
AU2013309872B2 (en) 2017-09-14
JPWO2014034902A1 (ja) 2016-08-08
AU2013309872A1 (en) 2015-03-19
HUE032816T2 (en) 2017-11-28
BR112015004459A2 (pt) 2017-07-04
ZA201501374B (en) 2016-03-30
EP2891651A1 (en) 2015-07-08
DK2891651T3 (en) 2017-06-06
PH12015500389A1 (en) 2015-04-27
WO2014034902A1 (ja) 2014-03-06
MX344385B (es) 2016-12-14
IL237432A0 (en) 2015-04-30
MY177737A (en) 2020-09-23
CA2882732A1 (en) 2014-03-06
EP2891651A4 (en) 2016-01-27
HK1210168A1 (en) 2016-04-15
TW201414722A (zh) 2014-04-16
RU2015111568A (ru) 2016-10-20
MX2015002209A (es) 2015-05-08
RU2658823C2 (ru) 2018-06-25
US20150218114A1 (en) 2015-08-06
IL237432B (en) 2019-05-30
BR112015004459B1 (pt) 2020-06-30

Similar Documents

Publication Publication Date Title
IL273276A (en) salt crystals
ZA201401268B (en) Noribogaine salt ansolvates
EP2915804A4 (en) NOVEL AMINE DERIVATIVE OR SALT OF IT
HK1201521A1 (en) Heterocyclic compounds and methods for their use
HK1201533A1 (en) Heterocyclic compounds and methods for their use
HK1201531A1 (en) Heterocyclic compounds and methods for their use
EP2886546A4 (en) Heterocyclic compound and use thereof
HK1207643A1 (en) Amides of 2-amino-4-arylthiazole compounds and their salts 2--4-
EP2938607A4 (en) CRYSTALLINE SALTS AND FORMS
PL2840907T3 (pl) Substytut soli
EP2902391A4 (en) NOVEL AMINO COMPOUND AND USE THEREOF
EP2935227A4 (en) DIAZOLAMIDE
HK1215571A1 (zh) 二鹽酸科比思特
EP2842937A4 (en) AMIN CONNECTION AND USE THEREOF FOR MEDICAL PURPOSES
EP2813508A4 (en) HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
HK1210168A1 (en) Amine salt and crystals thereof
GB201220447D0 (en) Releasable fastener
GB201219293D0 (en) Pyroelectric crystals